Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Citi lifts Phreesia stock target to $30 on growth prospects

EditorAhmed Abdulazez Abdulkadir
Published 03/15/2024, 06:09 AM
© Reuters.
PHR
-

On Friday, Citi maintained a positive outlook on Phreesia Inc . (NYSE:PHR), raising the price target on the healthcare technology firm's shares to $30 from $27, while reiterating a Buy rating. The adjustment follows Phreesia's recent earnings release, which reported revenue and adjusted EBITDA figures surpassing expectations.

The company's solid quarterly performance, highlighted by a year-over-year increase of 6% in subscription revenue per adjusted healthcare service client (AHSC) and a 5% rise in non-subscription (NS) revenue per visit, was a key factor in the analyst's reassessment.

These results support the belief in Phreesia's potential to execute its profitable growth strategy, aiming for over 20% growth while achieving profitability within the year.

The analyst's confidence is bolstered by management's commentary and subsequent discussions, which underscore Phreesia's trajectory towards significant profitability. The firm's ability to leverage general and administrative expenses is seen as a catalyst for margin expansion.

Looking forward, Citi expressed enthusiasm for Phreesia's capacity to monetize emerging products, such as the recently introduced Post-Script Engagement. This new offering is expected to find a market not only in life sciences but also in the pharmacy sector.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.